Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Paratek Pharma Inc (PRTK)

Paratek Pharma Inc (PRTK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Paratek Pharma Inc 75 PARK PLAZA BOSTON MA 02116 USA

www.paratekpharma.com P: 617-807-6600

Sector:

Medical

INDUSTRY GROUPING:

Medical - Biomedical

Description:

Paratek Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of therapeutics that treat infectious disease agents. The Company's lead product candidate, omadacycline, is a tetracycline-derived antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. Its second product candidate, WC 3035 is a tetracycline-derived compound designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals, Inc., formerly known as Transcept Pharmaceuticals, Inc., is based in United States.

Key Statistics

Overview:

Market Capitalization, $K 127,828
Enterprise Value, $K 350,408
Shares Outstanding, K 57,322
Annual Sales, $ 160,270 K
Annual Net Income, $ -63,570 K
Last Quarter Sales, $ 39,990 K
Last Quarter Net Income, $ -14,550 K
EBIT, $ -44,550 K
EBITDA, $ -44,060 K
60-Month Beta 1.70
% of Insider Shareholders 8.00%
% of Institutional Shareholders 53.60%
Float, K 52,736
% Float 92.00%
Short Volume Ratio 0.07

Growth:

1-Year Return -7.08%
3-Year Return -60.95%
5-Year Return -77.01%
5-Year Revenue Growth 1,169.97%
5-Year Earnings Growth 64.55%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.25 on 08/03/23
Next Earnings Date 11/02/23
Earnings Per Share ttm -1.10
EPS Growth vs. Prev Qtr 28.57%
EPS Growth vs. Prev Year 24.24%
Annual Dividend & Yield 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Most Recent Dividend 0.009 on 10/31/14
Dividend Payable Date 10/29/14
Dividend Payout Ratio 0.00%
Most Recent Split 1-12 on 10/31/14

PRTK Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % -40.05%
Profit Margin % -39.66%
Debt/Equity -0.47
Price/Sales 0.78
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -3.52
Interest Coverage -2.50
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar